Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.
Owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing T2DM
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mycoprotein | Active Comparator | 3 levels of mycoprotein will be consumed |
|
| control protein | Active Comparator | 3 levels of a control protein will be consumed |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| mycoprotein | Dietary Supplement |
| ||
| control protein |
| Measure | Description | Time Frame |
|---|---|---|
| Energy intake at ad-libitum meal | Energy intake will be assessed during an ad-libitum meal at 180 minutes at the end of each study visit. Participants will be offered a meal in excess and asked to eat until they feel comfortably full. The meal will be weighed before and after consumption and energy intake will be calculated from the manufacturer's reported nutritional composition. | upon completion of all participants, expected timeframe: 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Glucagon-like peptide-1 (GLP-1) | Plasma glucagon-like peptide-1 (GLP-1) concentrations will be measured by radioimmunoassay (RIA) at the end of the study | upon completion of all participants, expected at 2 years |
| peptide tyrosine-tyrosine (PYY) levels |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gary Frost | Imperial College London | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Imperial College NIHR CRF | London | W12 0NN | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27198187 | Result | Bottin JH, Swann JR, Cropp E, Chambers ES, Ford HE, Ghatei MA, Frost GS. Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial. Br J Nutr. 2016 Jul;116(2):360-74. doi: 10.1017/S0007114516001872. Epub 2016 May 20. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Nov 15, 2022 | |
| Reset | Sep 22, 2023 | |
| Release | Nov 28, 2024 | |
| Reset | Jan 15, 2025 | |
| Release | Mar 13, 2025 | |
| Reset | Mar 18, 2025 | |
| Release | Mar 31, 2025 | |
| Reset | Mar 31, 2025 | |
| Release | Jun 4, 2025 | |
| Reset | Jun 4, 2025 | |
| Release | Jun 5, 2025 | |
| Reset | Jun 5, 2025 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Nov 15, 2022 | Sep 22, 2023 | |||
| Nov 28, 2024 |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Plasma peptide tyrosine-tyrosine (PYY) concentrations will be measured by radioimmunoassay (RIA) at the end of the study |
| upon completion of all participants, expected at 2 years |
| Jan 15, 2025 |
| Mar 13, 2025 | Mar 18, 2025 |
| Mar 31, 2025 | Mar 31, 2025 |
| Jun 4, 2025 | Jun 4, 2025 |
| Jun 5, 2025 | Jun 5, 2025 |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |